Oxycodone immediate release - Purdue

Drug Profile

Oxycodone immediate release - Purdue

Alternative Names: OxiFast; OxiNorm; OxyFast; OxyGesic; OxyIR; OxylR; OxyNorm; S-8116; S-8117; S-811717

Latest Information Update: 05 Jan 2017

Price : $50

At a glance

  • Originator Purdue Pharma
  • Developer Mundipharma International; Napp Pharmaceutical Group; Purdue Pharma; Shionogi
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Pain
  • Phase III Back pain; Postoperative pain

Most Recent Events

  • 27 Dec 2016 Shionogi completes a phase III extension trial for Back pain in Japan (PO) (JapicCTI-132300)
  • 27 Dec 2016 Shionogi completes a phase III trial in Pain in Japan (PO) (JapicCTI132081)
  • 01 Nov 2015 Launched for Cancer pain in South Korea before November 2015 (PO and IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top